Combined paracrine and endocrine AAV9 mediated expression of hepatocyte growth factor for the treatment of renal fibrosis

Molecular Therapy

Volumn 18, Issue 7, 2010, Pages 1302-1309

  Schievenbusch, Stephanie ^a   Strack, Ingo ^a   Scheffler, Melanie ^a   Nischt, Roswitha ^a   Coutelle, Oliver ^a   Hösel, Marianna ^a   Hallek, Michael ^a   Fries, Jochen Wu ^a   Dienes, Hans Peter ^a   Odenthal, Margarete ^a   Büning, Hildegard ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN TYPE 1; COLLAGEN TYPE 1ALPHA 1; KSP CADHERIN; PARVOVIRUS VECTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; RECOMBINANT SCATTER FACTOR; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS; DRUG EFFICACY; GENE EXPRESSION; GENE LOCATION; GENE REPRESSION; GENE TARGETING; GENE THERAPY; GENE TRANSFER; GENETIC TRANSDUCTION; IMMUNOHISTOCHEMISTRY; KIDNEY FIBROSIS; LIVER PARENCHYMA; MOUSE; NONHUMAN; SEROTYPE; TRANSGENE; TREATMENT RESPONSE; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; AUTOANTIGENS; COLLAGEN TYPE IV; DEPENDOVIRUS; ENHANCER ELEMENTS, GENETIC; FIBROSIS; GENE EXPRESSION REGULATION; HEPATOCYTE GROWTH FACTOR; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY; KIDNEY DISEASES; LIVER; MICE; MICE, KNOCKOUT; POLYMERASE CHAIN REACTION; TRANSDUCTION, GENETIC;

MUS;

EID: 77954244202     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2010.71     Document Type: Article

References (50)

1. Collins, AJ, Foley, R, Herzog, C, Chavers, B, Gilbertson, D, Ishani, A et al. (2008). Excerpts from the United States Renal Data System 2007 annual data report. Am J Kidney Dis 51(1 suppl. 1): S1-320.
2. Wolf, G and Ziyadeh, FN (2007). Cellular and molecular mechanisms of proteinuria in diabetic nephropathy. Nephron Physiol 106: p26-p31.
3. Eddy, AA (2000). Molecular basis of renal fbrosis. Pediatr Nephrol 15: 290-301.
4. Inoue, T, Okada, H, Kobayashi, T, Watanabe, Y, Kanno, Y, Kopp, JB et al. (2003). Hepatocyte growth factor counteracts transforming growth factor-beta1, through attenuation of connective tissue growth factor induction, and prevents renal fbrogenesis in 5/6 nephrectomized mice. FASEB J 17: 268-270.
5. Matsumoto, K, Mizuno, S and Nakamura, T (2000). Hepatocyte growth factor in renal regeneration, renal disease and potential therapeutics. Curr Opin Nephrol Hypertens 9: 395-402.
6. Ramadori, G, Neubauer, K, Odenthal, M, Nakamura, T, Knittel, T, Schwögler, S et al. (1992). The gene of hepatocyte growth factor is expressed in fat-storing cells of rat liver and is downregulated during cell growth and by transforming growth factor-beta. Biochem Biophys Res Commun 183: 739-742.
7. Mizuno, S, Matsumoto, K and Nakamura, T (2001). Hepatocyte growth factor suppresses interstitial fbrosis in a mouse model of obstructive nephropathy. Kidney Int 59: 1304-1314.
8. Liu, KX, Kato, Y, Narukawa, M, Kim, DC, Hanano, M, Higuchi, O et al. (1992). Importance of the liver in plasma clearance of hepatocyte growth factors in rats. Am J Physiol 263(5 Pt 1): G642-G649.
9. Manno, CS, Pierce, GF, Arruda, VR, Glader, B, Ragni, M, Rasko, JJ et al. (2006). Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 12: 342-347.
10. Bainbridge, JW, Smith, AJ, Barker, SS, Robbie, S, Henderson, R, Balaggan, K et al. (2008). Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 358: 2231-2239.
11. Maguire, AM, Simonelli, F, Pierce, EA, Pugh, EN Jr, Mingozzi, F, Bennicelli, J et al. (2008). Safety and effcacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 358: 2240-2248.
12. Stroes, ES, Nierman, MC, Meulenberg, JJ, Franssen, R, Twisk, J, Henny, CP et al. (2008). Intramuscular administration of AAV1-lipoprotein lipase S447X lowers triglycerides in lipoprotein lipase-defcient patients. Arterioscler Thromb Vasc Biol 28: 2303-2304.
13. Wu, Z, Asokan, A and Samulski, RJ (2006). Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol Ther 14: 316-327.
14. Büning, H, Perabo, L, Coutelle, O, Quadt-Humme, S and Hallek, M (2008). Recent developments in adeno-associated virus vector technology. J Gene Med 10: 717-733.
15. Xia, JL, Dai, C, Michalopoulos, GK and Liu, Y (2006). Hepatocyte growth factor attenuates liver fbrosis induced by bile duct ligation. Am J Pathol 168: 1500-1512.
16. Franquesa, M, Alperovich, G, Herrero-Fresneda, I, Lloberas, N, Bolaños, N, Fillat, C et al. (2005). Direct electrotransfer of hHGF gene into kidney ameliorates ischemic acute renal failure. Gene Ther 12: 1551-1558.
17. Gao, G P, Alvira, MR, Wang, L, Calcedo, R, Johnston, J and Wilson, JM (2002). Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci USA 99: 11854-11859.
18. Gao, G, Vandenberghe, LH, Alvira, MR, Lu, Y, Calcedo, R, Zhou, X et al. (2004). Clades of Adeno-associated viruses are widely disseminated in human tissues. J Virol 78: 6381-6388.
19. Vandendriessche, T, Thorrez, L, Acosta-Sanchez, A, Petrus, I, Wang, L, Ma, L et al. (2007). Effcacy and safety of adeno-associated viral vectors based on serotype 8 and 9 vs. lentiviral vectors for hemophilia B gene therapy. J Thromb Haemost 5: 16-24.
20. Gross, O, Beirowski, B, Koepke, ML, Kuck, J, Reiner, M, Addicks, K et al. (2003). Preemptive ramipril therapy delays renal failure and reduces renal fbrosis in COL4A3-knockout mice with Alport syndrome. Kidney Int 63: 438-446.
21. Yang, J, Dai, C and Liu, Y (2001). Systemic administration of naked plasmid encoding hepatocyte growth factor ameliorates chronic renal fbrosis in mice. Gene Ther 8: 1470-1479. (Pubitemid 32994658)
22. Rabinowitz, JE, Rolling, F, Li, C, Conrath, H, Xiao, W, Xiao, X et al. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specifcity. J Virol 76: 791-801.
23. Shao, X, Johnson, JE, Richardson, JA, Hiesberger, T and Igarashi, P (2002). A minimal Ksp-cadherin promoter linked to a green fuorescent protein reporter gene exhibits tissue-specifc expression in the developing kidney and genitourinary tract. J Am Soc Nephrol 13: 1824-1836.
24. Gruh, I, Wunderlich, S, Winkler, M, Schwanke, K, Heinke, J, Blömer, U et al. (2008). Human CMV immediate-early enhancer: a useful tool to enhance cell-type-specifc expression from lentiviral vectors. J Gene Med 10: 21-32.
25. Schievenbusch, S, Strack, I, Scheffer, M, Wennhold, K, Maurer, J, Nischt, R et al. (2009). Profling of anti-fbrotic signaling by hepatocyte growth factor in renal fbroblasts. Biochem Biophys Res Commun 385: 55-61.
26. Tang, WW, Ulich, TR, Lacey, DL, Hill, DC, Qi, M, Kaufman, SA et al. (1996). Platelet-derived growth factor-BB induces renal tubulointerstitial myofbroblast formation and tubulointerstitial fbrosis. Am J Pathol 148: 1169-1180.
27. Akache, B, Grimm, D, Pandey, K, Yant, SR, Xu, H and Kay, MA (2006). The 37/67-kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8, 2, 3, and 9. J Virol 80: 9831-9836.
28. Thomas, CE, Storm, TA, Huang, Z and Kay, MA (2004). Rapid uncoating of vector genomes is the key to effcient liver transduction with pseudotyped adeno-associated virus vectors. J Virol 78: 3110-3122.
29. Takeda, S, Takahashi, M, Mizukami, H, Kobayashi, E, Takeuchi, K, Hakamata, Y et al. (2004). Successful gene transfer using adeno-associated virus vectors into the kidney: comparison among adeno-associated virus serotype 1-5 vectors in vitro and in vivo. Nephron Exp Nephrol 96: e119-e126.
30. Lipkowitz, MS, Hanss, B, Tulchin, N, Wilson, PD, Langer, JC, Ross, MD et al. (1999). Transduction of renal cells in vitro and in vivo by adeno-associated virus gene therapy vectors. J Am Soc Nephrol 10: 1908-1915.
31. Kern, A, Schmidt, K, Leder, C, Müller, OJ, Wobus, CE, Bettinger, K et al. (2003). Identifcation of a heparin-binding motif on adeno-associated virus type 2 capsids. J Virol 77: 11072-11081.
32. White, SJ, Nicklin, SA, Büning, H, Brosnan, MJ, Leike, K, Papadakis, ED et al. (2004). Targeted gene delivery to vascular tissue in vivo by tropism-modifed adeno-associated virus vectors. Circulation 109: 513-519.
33. Perabo, L, Goldnau, D, White, K, Endell, J, Boucas, J, Humme, S et al. (2006). Heparan sulfate proteoglycan binding properties of adeno-associated virus retargeting mutants and consequences for their in vivo tropism. J Virol 80: 7265-7269.
34. Wang, Z, Zhu, T, Qiao, C, Zhou, L, Wang, B, Zhang, J et al. (2005). Adeno-associated virus serotype 8 effciently delivers genes to muscle and heart. Nat Biotechnol 23: 321-328.
35. Vandenberghe, LH, Wilson, JM and Gao, G (2009). Tailoring the AAV vector capsid for gene therapy. Gene Ther 16: 311-319.
36. Liu, Y, Tolbert, EM, Lin, L, Thursby, MA, Sun, AM, Nakamura, T et al. (1999). Up-regulation of hepatocyte growth factor receptor: an amplifcation and targeting mechanism for hepatocyte growth factor action in acute renal failure. Kidney Int 55: 442-453.
37. Yanagita, K, Nagaike, M, Ishibashi, H, Niho, Y, Matsumoto, K and Nakamura, T (1992). Lung may have an endocrine function producing hepatocyte growth factor in response to injury of distal organs. Biochem Biophys Res Commun 182: 802-809.
38. Kono, S, Nagaike, M, Matsumoto, K and Nakamura, T (1992). Marked induction of hepatocyte growth factor mRNA in intact kidney and spleen in response to injury of distant organs. Biochem Biophys Res Commun 186: 991-998.
39. Miyazawa, K, Shimomura, T, Naka, D and Kitamura, N (1994). Proteolytic activation of hepatocyte growth factor in response to tissue injury. J Biol Chem 269: 8966-8970.
40. Miyazawa, K, Shimomura, T and Kitamura, N (1996). Activation of hepatocyte growth factor in the injured tissues is mediated by hepatocyte growth factor activator. J Biol Chem 271: 3615-3618.
41. Takayama, H, LaRochelle, WJ, Sharp, R, Otsuka, T, Kriebel, P, Anver, M et al. (1997). Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. Proc Natl Acad Sci USA 94: 701-706.
42. Yazawa, K, Isaka, Y, Takahara, S, Imai, E, Ichimaru, N, Shi, Y et al. (2004). Direct transfer of hepatocyte growth factor gene into kidney suppresses cyclosporin A nephrotoxicity in rats. Nephrol Dial Transplant 19: 812-816.
43. Yang, J and Liu, Y (2002). Blockage of tubular epithelial to myofbroblast transition by hepatocyte growth factor prevents renal interstitial fbrosis. J Am Soc Nephrol 13: 96-107.
44. Yang, J and Liu, Y (2003). Delayed administration of hepatocyte growth factor reduces renal fbrosis in obstructive nephropathy. Am J Physiol Renal Physiol 284: F349-F357.
45. Hacker, UT, Wingenfeld, L, Kofer, DM, Schuhmann, NK, Lutz, S, Herold, T et al. (2005). Adeno-associated virus serotypes 1 to 5 mediated tumor cell directed gene transfer and improvement of transduction effciency. J Gene Med 7: 1429-1438.
46. Samulski, RJ, Chang, LS and Shenk, T (1989). Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression. J Virol 63: 3822-3828.
47. Xiao, X, Li, J and Samulski, RJ (1998). Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 72: 2224-2232.
48. Shi, W, Arnold, GS and Bartlett, JS (2001). Insertional mutagenesis of the adeno-associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors targeted to alternative cell-surface receptors. Hum Gene Ther 12: 1697-1711.
49. Girod, A, Ried, M, Wobus, C, Lahm, H, Leike, K, Kleinschmidt, J et al. (1999). Genetic capsid modifcations allow effcient re-targeting of adeno-associated virus type 2. Nat Med 5: 1438.
50. Zolotukhin, S, Byrne, BJ, Mason, E, Zolotukhin, I, Potter, M, Chesnut, K et al. (1999). Recombinant adeno-associated virus purifcation using novel methods improves infectious titer and yield. Gene Ther 6: 973-985.